|
|
|
04.03.26 - 13:03
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,850 shares of BioCryst common stock. The RSUs were granted as of March 2, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
|
|
17.02.26 - 13:03
|
BioCryst to Present at Upcoming Investor Conference (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026, at 9:10 a.m. ET....
|
|
|
|
|
|
|
04.02.26 - 14:30
|
Will BioCryst′s ORLADEYO Hit The $1 Billion Sales Mark? (RTTNews)
|
|
|
Shares of BioCryst Pharmaceuticals Inc. (BCRX) are down over 40% from their 52-week high of $11.31, recorded last June, and trade around $6. The company's core marketed drug is ORLADEYO, a plasma kallikrein inhibitor approved for the prophylaxis of hereditary angioedema. Net product sales of ORLADEYO have increased steadily each year....
|
|
|
|
|
21.01.26 - 22:03
|
Astria Stockholders Vote to Approve Acquisition by BioCryst (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the “Merger”).
The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, whose mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Astria's lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Astria's second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis.
Cautionary Note Regarding Forward-Looking Statements
Statements included in t...
|
|
|
|
|
|
|
|
|
06.01.26 - 13:03
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted one newly-hired employee restricted stock units (RSUs) covering an aggregate of 18,300 shares of BioCryst common stock. The RSUs were granted as of January 2, 2026, as inducements material to such employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
